Guerbet Reports Stable H1 2026 Revenue Amid Regional Challenges
Event summary
- H1 2026 revenue of €379.2m, nearly stable at -0.1% CER and like-for-like.
- Q2 decline of 2.5% driven by Asia contraction (-14.0%) offset by Americas recovery (+4.8%).
- Full-year guidance: revenue stable or slightly down; EBITDA margin ~8% including €35m Raleigh remediation costs.
- Secured waiver on financial debt ratio covenants, refinancing discussions underway by October 2026.
The big picture
Guerbet's stable H1 performance reflects contrasting regional pressures, with Asia's healthcare reforms requiring commercial adjustments. The company's ability to navigate these dynamics while executing its transformation plan will be critical amid ongoing financial restructuring discussions. Scale remains modest at ~€786m annual revenue.
What we're watching
- Regional Recovery
- Whether Guerbet can sustain Americas momentum while addressing Asia's structural challenges.
- Financial Flexibility
- The terms of refinancing negotiations and impact on debt ratios by October 2026.
- Operational Normalization
- Progress at Raleigh site and FDA inspection readiness by year-end.
Related topics